Mineralys Therapeutics, Inc. MLYS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.15M+11.7% | $1.03M-15.1% | $1.21M+20.2% | $1.01M-25.1% | $1.35M+103% | ||
| $652.47M-1.3% | $661.39M+10.3% | $599.8M+78.9% | $335.27M-5.4% | $354.51M+72.6% | ||
| $32K-15.8% | $38K+443% | $7K-68.2% | $22K-42.1% | $38K-28.3% | ||
| —— | —— | —— | —— | —— | ||
| $652.86M-1.4% | $661.81M+10.3% | $599.95M+78.7% | $335.72M-5.4% | $354.94M+72.4% | ||
| $1.12M-44.7% | $2.02M+79.9% | $1.12M-64.6% | $3.16M+748% | $373K-22.1% | ||
| $14.72M-2.6% | $15.11M-35.7% | $23.52M+6.1% | $22.17M+65.6% | $13.39M-8.6% | ||
| 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | ||
| -$496.51M-8.6% | -$457.17M-7.6% | -$424.94M-9.5% | -$388M-12.6% | -$344.73M-14.0% | ||
| $638.14M-1.3% | $646.69M+12.2% | $576.43M+83.8% | $313.55M-8.2% | $341.56M+78.6% | ||
| $652.86M-1.4% | $661.81M+10.3% | $599.95M+78.7% | $335.72M-5.4% | $354.94M+72.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Mineralys Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 44.33 — current assets exceed current liabilities.
- Where does Mineralys Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.